LYTIR

Insider · SEC Form 4 · Chief Executive Officer

Lawrence Otto Klein

Filed with the SEC as Klein Lawrence Otto; the order above is the one the filer's own signature uses.

In the 12 months to Nov 8, 2026, on the open market: sold $11.7M of ORKA. Filed a median of 0 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $11.7M in total.Jun: Insider sales $120KSep: Insider sales $7.1MOct: Insider sales $2.1MNov: Insider sales $2.4MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $11.7M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. ORKASold: Oruka Therapeutics, Inc. Nov 2, 2026 25,000 shares filed Nov 2, 2026 5 transactions 10b5-1 plan filing $2.4M
  2. ORKASold: Oruka Therapeutics, Inc. Oct 1, 2026 25,000 shares filed Oct 2, 2026 3 transactions 10b5-1 plan filing $2.1M
  3. ORKASold: Oruka Therapeutics, Inc. Sep 15, 2026 2,452 shares filed Sep 15, 2026 923,128 shares held directly after, as filed filing $235K
  4. ORKASold: Oruka Therapeutics, Inc. Sep 1, 2026 75,000 shares filed Sep 1, 2026 3 transactions 10b5-1 plan filing $6.9M
  5. ORKASold: Oruka Therapeutics, Inc. Jun 15, 2026 1,729 shares filed Jun 15, 2026 925,580 shares held directly after, as filed filing $120K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • ORKA: option exercise or conversion (code M), 3 entries, Sep 1 to Nov 2, 2026
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.